Therapeutics and Clinical Risk Management (Nov 2023)

Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study

  • Achalu DL,
  • Mohammed FG,
  • Teferi M

Journal volume & issue
Vol. Volume 19
pp. 889 – 901

Abstract

Read online

Daniel Legese Achalu,1 Foziya Getachew Mohammed,2 Mekonnen Teferi1 1Clinical Trial Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia; 2Knowledge Management Directorate, Armauer Hansen Research Institute, Addis Ababa, EthiopiaCorrespondence: Daniel Legese Achalu, Tel +251912750932, Email [email protected]: Since its launch as a standardized treatment for multidrug-resistant tuberculosis (MDR-TB) in Ethiopia in April 2018, the safety profile of the shorter injectable regimen under a programmatic setting has not been well studied. Thus, this study aimed to assess the status of adverse events in patients treated with a shorter injectable regimen in Ethiopia.Methods: This is a retrospective cohort study. Data were collected using a structured data abstraction form and analyzed using SPSS, version 25, both descriptively and analytically. Logistic regression was conducted to assess predictors, and Kaplan–Meier analysis was used to examine the time to AEs and survival experiences.Results: Of 256 patients, 245 (95.7%) were eligible for the study. Of 245, 107 (43.7%) patients experienced at least one AE. In total, 276 AE cases were observed out of which the most common were nausea/vomiting (20.3%), dyspepsia (18.1%), and ototoxicity (11.6%). Of 276 AEs, approximately 49 (17.8%) were serious. AEs led to drug discontinuation, dose modification, and regimen change in 29 (27%), 15 (14%) and 10 (9.3%) patients, respectively. Only 19.2% of 276 the overall AEs and 22.6% of 62 AE of special interest (AESI) were reported to the National Pharmacovigilance Center.Conclusion: Although the observed extent of AEs associated with the shorter regimen (SR) seemed to be moderate, it significantly influenced the treatment schemes and patient conditions. Reporting of AEs was low, irrespective of their severity and AESI. Therefore, strengthening the implementation of active drug safety monitoring and management is required.Keywords: adverse events, adverse event of special interest, drug resistant tuberculosis, injectable, serious adverse event and shorter regimen

Keywords